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Abstract
PURPOSE—To compare the late complications in the Ahmed Baerveldt Comparison Study 
during 5 years of follow-up.
DESIGN—Multicenter, prospective, randomized clinical trial.
METHODS
SETTINGS: Sixteen international clinical centers.
STUDY POPULATION: Two hundred seventy six subjects aged 18 to 85 years with previous 
intraocular surgery or refractory glaucoma with intraocular pressure of > 18 mmHg.
INTERVENTIONS: Ahmed Glaucoma Valve FP7 or Baerveldt Glaucoma Implant BG 101-350.
MAIN OUTCOME MEASURES: Late postoperative complications (beyond 3 months), 
reoperations for complications, and decreased vision from complications.
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RESULTS—Late complications developed in 56 subjects (46.8 ± 4.8 5 year cumulative % ± SE) 
in the Ahmed Glaucoma Valve group and 67 (56.3 ± 4.7 5 year cumulative % ± SE) in the 
Baerveldt Glaucoma Implant group (P = 0.082). The cumulative rates of serious complications 
were 15.9% and 24.7% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups 
respectively (P = 0.034) although this was largely driven by subjects who had tube occlusions in 
the two groups (0.8% in the Ahmed Glaucoma Valve group and 5.7% in the Baerveldt Glaucoma 
Implant group, P = 0.037). Both groups had a relatively high incidence of persistent diplopia 
(12%) and corneal edema (20%), although half of the corneal edema cases were likely due to pre-
existing causes other than the aqueous shunt. The incidence of tube erosion was 1% and 3% in the 
Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P = 0.04).
CONCLUSIONS—Long term rates of vision threatening complications and complications 
resulting in reoperation were higher in the Baerveldt Glaucoma Implant than the Ahmed 
Glaucoma Valve group over 5 years of follow-up.
INTRODUCTION
The use of aqueous shunts for surgical glaucoma management has increased dramatically in 
the past 20 years. In a recent analysis of the U.S. Medicare database, the number of aqueous 
shunt implantations performed annually has risen from 2,356 in 1994 to 12,021 in 2012.1 
There are numerous aqueous shunts in use but, at least in the U.S. market, two models are 
used most commonly, the Ahmed Valve model FP7 (New World Medical, Rancho 
Cucamonga, CA) and the Baerveldt BG 101-350 (Abbott Medical Optics, Abbott Park, IL). 
A 2008 survey of the American Glaucoma Society membership showed that approximately 
half of respondents favored the Ahmed Glaucoma Valve and half preferred the Baerveldt 
Glaucoma Implant when operating on patients with previous incisional eye surgery or 
refractory glaucoma.2 In that same year, the American Academy of Ophthalmology 
published a Technology Assessment article reviewing aqueous shunts and concluded that 
“Too few high-quality direct comparisons of various available shunts have been published to 
assess the relative efficacy or complication rates of specific devices….”3 While there have 
been several retrospective studies comparing the Ahmed and Baerveldt implants, these have 
been of relatively short duration and inconclusive as to the relative success rates and 
complications of these two implants.4–8 In addition, these earlier studies used older models 
with different materials and designs, which have been improved upon to address prior 
concerns. Lastly, these studies suffer from the selection bias inherent to all retrospective 
analyses of existing medical record data.
The Ahmed Baerveldt Comparison (ABC) Study was a prospective multicenter randomized 
surgical trial that compared the safety and efficacy of the Ahmed Glaucoma Valve FP7 and 
Baerveldt Glaucoma Implant BG 101-350 in patients with previous incisional eye surgery or 
refractory glaucoma.9 These two implants have markedly different design features. The 
Ahmed Glaucoma Valve FP7 is a valved implant with a 184mm2 endplate and the Baerveldt 
Glaucoma Implant BG 101-350 is a non-valved implant with a 350mm2 endplate. At five 
years, the Baerveldt Glaucoma Implant group had an average IOP that was 2 mmHg lower 
than the Ahmed Glaucoma Valve FP7 group and, at most time points, subjects in the 
Baerveldt Glaucoma Implant BG 101-350 group were, on average, taking fewer medications 
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than the Ahmed Glaucoma Valve FP7 group.10 Over the five years of follow-up, the two 
treatment groups failed at the same rate, approximately 8% per year, but failures in the two 
groups occurred for different reasons. Subjects in the Ahmed Glaucoma Valve FP7 group 
failed more often than the Baerveldt Glaucoma Implant BG 101-350 group due to high IOP 
endpoints (persistently elevated IOP and reoperation for IOP elevation), while subjects in the 
Baerveldt Glaucoma Implant BG 101-350 group failed more often than the Ahmed 
Glaucoma Valve FP7 group due to safety endpoints such as persistent hypotony or loss of 
light perception vision.
However, in any surgical comparison study, it is important to weigh the relative efficacy 
against the relative risks of each procedure. The intraoperative and early postoperative 
complications (within three months of surgery) in the ABC study were reported along with 
the one-year outcomes.11 The purpose of the current study was to examine the long-term 
(five-year) complications of the Ahmed FP7 and Baerveldt BG 101-350 implants in subjects 
with prior incisional surgery or refractory glaucoma.
METHODS
This prospective randomized prospective clinical trial was approved at the Institutional 
Review Boards at 16 clinical centers and each patient gave informed consent. The study was 
registered at www.clinicaltrials.gov (identifier NCT00376363). The design and methods of 
the ABC Study are described in detail in the baseline methodology paper,9 and are 
summarized as follows.
Randomization, Eligibility, and Treatment
Subjects age 18–85 years with refractory glaucoma and IOPs greater than or equal to 18 
mmHg in whom aqueous shunt surgery was planned were enrolled in the study. Subjects 
with primary glaucomas with a previous failed trabeculectomy or who had previous 
intraocular surgery were included. Also, subjects without previous intraocular surgery were 
eligible if they had secondary glaucomas known to be refractory to trabeculectomy such as 
neovascular glaucoma (NVG), uveitic glaucoma, or glaucoma associated with iridocorneal 
endothelialization (ICE) syndrome.
Individuals enrolled in the study were randomized in a 1:1 ratio to placement of an Ahmed 
Glaucoma Valve FP7 or Baerveldt Glaucoma Implant BG 101-350 according to a permuted 
variable block randomization scheme, stratified by surgeon within one of 16 clinical centers 
and type of glaucoma. Subjects were allocated to one of 4 strata according to their type of 
glaucoma, as follows: (1) Primary glaucomas with previous intraocular surgery; (2) 
Secondary glaucomas (excluding uveitic glaucoma and NVG); (3) NVG; and (4) Uveitic 
glaucoma. Subjects were excluded if they lacked light perception vision, were unwilling or 
unable to give informed consent, lived out of the area and were expected to be unavailable 
for follow-up visits, underwent a previous cyclodestructive procedure or previous aqueous 
shunt implanted in the same eye, underwent a prior scleral buckling procedure or other 
external impediment to superotemporal device implantation, had silicone oil in the eye, had 
vitreous in the anterior chamber sufficient to require a vitrectomy, had uveitis associated 
with a systemic condition like juvenile rheumatoid arthritis, had nanophthalmos, had Sturge-
Budenz et al. Page 3
Am J Ophthalmol. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Weber syndrome or other conditions associated with elevated episcleral venous pressure, or 
needed aqueous shunt surgery combined with other ocular procedures. For subjects in whom 
both eyes were eligible for enrollment, only the first eligible eye to be implanted was 
enrolled. Neither the subject nor investigator was masked to the randomization assignment. 
Details of the surgical procedures for Ahmed Glaucoma Valve and Baerveldt Glaucoma 
Implant BG 101-350 implantation used in this study are described in the baseline paper.9
Patient Visits
Follow-up visits were scheduled one day, one week, one month, three months, six months, 
one year, 18 months, two years, three years, four years, and five years postoperatively. 
Detailed information about data obtained at baseline and follow-up visits is contained in the 
baseline paper.9
Postoperative Interventions
At each follow-up visit, investigators were asked about interventions performed since the 
subject’s last visit. There were specific questions about whether anterior chamber 
reformation or intravitreal injections had been performed as well as an open ended “Other 
Interventions” category. Postoperative interventions were counted as such in the analysis if 
the intervention was deemed related to the original surgery, needed for further IOP lowering 
but not incisional surgery (such as laser trabeculoplasty), or needed for a complication of the 
surgery.
Definition of Complications
The current analysis only includes reoperations or loss of vision if they were attributable to 
the aqueous shunt surgery. Early complications were those that were recorded by the 3-
month follow-up visit. These were reported in the 1-year outcomes paper.11 Late 
complications were those that were experienced after the 3-month followup visit. A serious 
complication was defined as any complication, early or late, that was associated with a 2-
line Snellen acuity decrease or a return to the operating room for a surgical procedure to 
manage the complication. A revision in the operating room to manage an occluded tube was 
considered a reoperation for a complication. The Snellen visual acuity (VA) decrease was 
assessed at the 5-year visit. If the patient did not have a 5-year visit, then the patient’s 
complication could not be categorized as serious by vision loss, but could by virtue of 
reoperation.
Statistical Analysis
Univariate comparisons between treatment groups were made using the 2-sided Student t 
test, X2 test, or Fisher exact test. Subjects’ data were analyzed in the group to which they 
were assigned during randomization (intent-to-treat analysis). A P value of 0.05 or less was 
considered statistically significant in our analyses.
RESULTS
A total of 276 subjects were enrolled between October 2006 and April 2008. One hundred 
forty three subjects (52%) were randomly assigned to placement of an Ahmed Glaucoma 
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Valve FP7 and 133 (48%) to a Baerveldt Glaucoma Implant BG 101-350. The disposition of 
subjects is summarized in the Consort Flow Diagram (Supplemental material available at 
AJO.com). Intraoperative complications,9 early postoperative complications,11 and visual 
acuity results10 have been described in detail previously.
Postoperative Interventions
Table 1 lists postoperative interventions that occurred over 5 years of follow-up, excluding 
those included in the1 year report.11 The total number of subjects requiring interventions 
beyond one year was 16 in the Ahmed Glaucoma Valve FP7 group and 25 in the Baerveldt 
Glaucoma Implant BG 101-350 group, a difference that was not statistically significant (P = 
0.21, Fishers Exact Test). Excluding cataract extraction (detailed below), there were only 
seven surgical interventions needed between three and five years of follow-up.
Late Postoperative Complications
Table 2 details the cumulative five year incidence of late (after 3 months) complications by 
randomized treatment group. Late complications developed in 56 subjects (46.8 ± 4.8 5 year 
cumulative % ± SE) in the Ahmed Glaucoma Valve group and 67 subjects (56.3 ± 4.7 5 year 
cumulative % ± SE) in the Baerveldt Glaucoma Implant BG 101-350 group during 5 years 
of follow-up (P = 0.082). The overall incidence of late postoperative complications was 
similar between treatment groups.
Tube occlusion (p = 0.037, Fisher’s exact test) and phthisis bulbi (p = 0.037, Fisher’s exact 
test) were late postoperative complications that occurred with significantly greater frequency 
in the Baerveldt Glaucoma Implant BG 101-350 group than the Ahmed Glaucoma Valve 
group. The issue of tube occlusion was discussed in the 1-year outcomes paper11 and there 
were no additional tube occlusions beyond the 1 year time point. Phthisis bulbi was found in 
6 subjects in the Baerveldt Glaucoma Implant BG 101-350 group compared to 1 subject in 
the Ahmed Glaucoma Valve FP7 group. These same subjects were counted as failures due to 
persistent hypotony due to severe vision loss in all of these subjects.
Persistent corneal edema was found in 20.1% and 20.4% of subjects in the Ahmed 
Glaucoma Valve FP7and Baerveldt Glaucoma Implant BG 101-350 groups, respectively, 
although this was attributed to non-implant causes in 50% of these so the percentage of 
subjects with persistent corneal edema attributable to the aqueous shunt was closer to 12%. 
Diplopia was found in 12.7% and 11.8% of subjects in the Ahmed Glaucoma Valve FP7 and 
Baerveldt Glaucoma Implant BG 101-350 groups, respectively, and there was no difference 
between the two groups in the incidence of diplopia. Cystoid macular edema was the third 
most frequent complication, occurring in 6.2% of subjects in the Ahmed Glaucoma Valve 
group and 7.2% of subjects in the Baerveldt Glaucoma Implant BG 101-350 group. It was 
difficult to determine whether this was surgically related or caused by underlying conditions 
such as diabetic retinopathy, uveitis, or neovascular glaucoma, all of which were common in 
this cohort and are also associated with cystoid macular edema.
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Serious Complications
Table 3 shows serious complications resulting in reoperation and/or vision loss. 
Complications were classified as serious if they were associated with either reoperation for 
complication or if they were associated with a Snellen acuity loss of 2 or more lines at their 
last study visit that could be attributed to a complication of tube implantation. The incidence 
of serious complications was higher in the Baerveldt Glaucoma Implant BG 101-350 group. 
Serious complications were observed in 17 (15.9%) subjects in the Ahmed Glaucoma Valve 
group and 29 (24.7%) subjects in the Baerveldt Glaucoma Implant BG 101-350 group (p = 
0.034, log rank test adjusted for stratum). Figure 1 shows the cumulative rates of serious 
complications for each group. Persistent corneal edema was the most common cause for 
both reoperation for a complication and loss of 2 or more lines of Snellen VA in both groups 
(Table 3). As reported previously,10 approximately 40% of subjects in both groups lost 2 or 
more lines of Snellen VA after five years, but the vast majority of these were attributable to 
their underlying ocular disease rather than the aqueous shunt surgery. Sixteen subjects in the 
Ahmed Glaucoma Valve group and 24 subjects in the Baerveldt Glaucoma Implant BG 
101-350 group underwent reoperations for complications. A total of 22 eyes experienced 
complications during follow up resulting in the loss of 2 or more lines of Snellen VA. The 
study PI (DLB) reviewed all of these, masked to randomized treatment assignment and the 
first three months of follow up (during which eyes implanted with Baerveldt tubes could be 
expected to have high IOP), and attributed the acuity loss to glaucoma progression (N = 4; 
Ahmed Glaucoma Valve FP7:3, Baerveldt Glaucoma Implant BG 101-350:1), progressive 
retinal disease (N = 4; Ahmed Glaucoma Valve FP7:2, Baerveldt Glaucoma Implant BG 
101-350:2), other causes (N = 7; Ahmed Glaucoma Valve FP7:2, Baerveldt Glaucoma 
Implant BG 101-350:5), and in one case the cause could not be determined as follow up 
information was obtained from a non-study ophthalmologist. The other causes of acuity loss 
not attributed to the GDI implantation included corneal decomposition secondary to ICE (N 
= 2), corneal epitheliopathy secondary to dry eye (N = 1), pre-existing corneal disease (N = 
2), posterior corneal opacification (N = 1), and aphakia (N = 1).
Reoperation for Complications
At year five, the cumulative proportion (SE) of subjects with complication-related 
reoperations, including explantations, in the Ahmed Glaucoma Valve group was 14.3% 
(3.5%), N = 16, compared to 19.5% (3.6%), N = 24, in the Baerveldt Glaucoma Implant BG 
101-350 group (p = 0.109, log-rank test). Figure 2 shows the cumulative proportion of 
subjects in each group who required reoperation for a complication throughout five years of 
follow-up. The risk ratio was 0.60 with 95% confidence interval 0.32 to 1.13 (Cox 
proportional hazard regression), so a clinically significant difference in favor of Ahmed 
Glaucoma Valve implantation having a risk that was 1/3rd that of Baerveldt Glaucoma 
Implant BG 101-350 implantation with respect to complication reoperations cannot be 
excluded. There was no significant difference by stratum (p = 0.98, cox regression 
accounting for randomized treatment group), nor was there a significant interaction between 
randomized treatment group and stratum (p = 0.38, cox regression). This implies that 
diagnostic stratum, particularly neovascular glaucoma, did not affect the likelihood of 
having a reoperation for complications. After 5 years of follow up there were no significant 
differences (all p>0.1) in rates of late onset complications between clinical centers or 
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between surgeons more experienced with the randomized aqueous shunt (≥20 prior 
implantations) compared to those with less experience.
Table 4 outlines the specific operations performed for complications in each of the two 
groups. Figure 2 presents the cumulative rates of reoperation for complications in the two 
groups. The higher rate of complications in the Baervledt Glaucoma Implant BG 101-350 
group, which approached statistical significance at three years (p = 0.053, log-rank test12), 
decreased at five years (p = 0.109, log-rank test) although the 95% confidence interval 
around the relative risk (1.67, Cox survival regression) of increased complications resulting 
in reoperation in the Baerveldt Glaucoma Implant BG 101-350 group still includes a 
possibly substantially higher risk (95% CI:0.9, 3.1).
Cataract Surgery during Follow-Up
There were 91 phakic eyes enrolled. Of those, 34 had cataract extraction, censored at 
glaucoma reoperation. Seventeen were in the Ahmed Glaucoma Valve FP7 group and 17 
were in the Baerveldt Glaucoma Implant BG 101-350 group. The cumulative proportions 
receiving cataract extraction at 5 years were 49.5% (SE = 9.0%) and 43.6% (SE = 8.1%) in 
the Ahmed Glaucoma Valve FP7 and Baerveldt Glaucoma Implant BG 101-350 groups, 
respectively (P = 0.88, log rank test, Figure 3).
DISCUSSION
The ABC Study is the largest and longest prospective clinical trial comparing two aqueous 
shunts, with an enrollment of 276 subjects followed over 5 years. The study was designed to 
compare the safety and efficacy of the Ahmed Glaucoma Valve model FP7 and the Baerveldt 
Glaucoma Implant BG 101-350. The 5 year treatment outcomes, reported earlier, found that 
the Baerveldt Glaucoma Implant BG 101-350 had fewer failures over time with a slightly 
lower average IOP (2 mmHg) on fewer medications at most time points.10 However, 
previous reports on the safety of these two implants at 1 and 3 years have shown a higher 
incidence of interventions and serious vision-threatening complications with the Baerveldt 
Glaucoma Implant BG 101-350 compared with the Ahmed Glaucoma Valve FP7.10–14 In the 
analysis of complications out to 5 years, this trend continued in the ABC study, with more 
subjects in the Baerveldt Glaucoma Implant BG 101-350 group undergoing reoperation for 
implant-related complications as well as loss of 2 or more lines of visual acuity related to 
implant complications.
There appeared to be more tube occlusions in the Baerveldt Glaucoma Implant BG 101-350 
group (6) compared to the Ahmed Glaucoma Valve FP7 group (1) for reasons that are 
unclear. In addition, there were more cases of phthisis bulbi in the Baerveldt Glaucoma 
Implant BG 101-350 group (6) than the Ahmed Glaucoma Valve FP7 group (1), perhaps due 
to the fact that the Baerveldt Glaucoma Implant BG 101-350 group had a similar proportion 
of subjects experiencing failures due to persistent hypotony. It may be that the larger end 
plate of the Baerveldt Glaucoma Implant BG 101-350 implant, which is generally 
considered to provide lower long-term IOPs,15 appears to put patients at increased risk of 
persistent hypotony and phthisis bulbi as well.
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Corneal edema has been a concern after aqueous shunt surgery, primarily through loss of 
endothelial cell density, which has been demonstrated to occur.16–18 We found a 20% rate of 
persistent corneal edema after tube implantation in the current study at 5 years. This was 
similar to the 5-year rate in the tube group in the TVT study, which was 16%.19 We did not 
find a difference between the two treatment arms in the ABC study, however. When we 
examined the reason for corneal edema, half of the cases had a reason other than the 
presence of a tube in the anterior chamber that could have explained the corneal edema such 
as pre-existing corneal transplants which could have failed, pre-existing corneal diagnoses 
such as ICE syndrome, or the presence of an anterior chamber intraocular lens, all of which 
are equally as likely to cause persistent corneal edema. In the 5-year TVT results,19 the tube 
and trabeculectomy groups had the same rate of persistent corneal edema, suggesting that 
corneal edema may not be related simply to the presence of a tube in the anterior chamber 
but possibly due to hypotony or pre-existing conditions. Results from the GDI arm of the 
ongoing Primary Tube Versus Trabeculectomy study, which enrolled subjects without prior 
intraocular surgery and without high risk for treatment failures, may help elucidate this 
issue.
Late-onset endophthalmitis, a significant concern following trabeculectomy, particularly in 
the antifibrotic era,20 was seen in only 1 of the 276 subjects in the current study. This may be 
because of the early and aggressive intervention for exposed implant tubes and explants 
practiced as part of current practice patterns.21 It seems that the concerns regarding long-
term endophthalmitis with relation to trabeculectomy do not follow for aqueous shunts.
Diplopia is a more common complication of glaucoma surgery performed with GDIs 
compared to trabeculectomy22 and, indeed, the 5-year results of the TVT study found a three 
times greater incidence in the tube (6%), compared to the trabeculectomy (2%), group.19 
The current study found an equal, approximate 12% cumulative risk of persistent diplopia in 
the two groups, contrary to older, non-randomized studies that found a higher incidence with 
the Baerveldt Glaucoma Implant than the Ahmed Glaucoma Valve.23 However, these older 
reports were all based on the old design of the Baerveldt Glaucoma Implant, which did not 
have fenestrations in the end plate, specifically designed to reduce the height of the bleb and 
minimize restrictive strabismus. The cause of diplopia in patients undergoing GDIs is likely 
a restrictive strabismus, either from the bleb itself or the plate impinging on the muscle 
insertion.22 Unlike the TVT Study, the current study did not do formal motility examination 
but relied on a forced choice question regarding double vision conducted at each visit. 
Assessing motility disturbances in this way might actually underestimate the true incidence 
of motility disturbances, particularly since patients with refractory glaucomas like those in 
the current study may have advanced visual field loss from glaucoma or central visual acuity 
loss from other underlying conditions and may even be monocular. The risk of diplopia is 
significantly high and relatively unique to aqueous shunts to warrant discussion of this 
possibility during the risk/benefit discussion with patients preoperatively, at least in those 
with good binocular vision.
Tube and plate erosion are a concern when using an extraocular implant. Prior to the use of 
tissue patch graft material to cover the tube, the initial experience with GDIs showed a tube 
erosion rate of 30%.24 The rate in the current series at 5 years was 3% in the Ahmed 
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Glaucoma Valve FP7 group and 1% in the Baerveldt Glaucoma Implant BG 101-350 group. 
In all cases, scleral reinforcement with a tissue patch was used. At 5 years, the rate in the 
Baerveldt Glaucoma Implant BG 101-350 group of the TVT study was 5%.19 Previously 
identified risk factors for erosion include prior ocular surgery, neovascular glaucoma, 
Hispanic ancestry, and combining GDI with another surgery.25,26 The mechanism for tube 
erosion has been postulated to be either mechanical or immunological.27,28 Unproven 
strategies for reducing the risk of tube erosion include routing the tube directly superiorly to 
reduce rubbing by the eyelid margin, placing the tube in the sulcus when possible, or 
tunneling the tube and also covering it with a tissue patch graft.
The ABC Study has several limitations. First, there was no ability to mask subjects or 
investigators to the treatment assignment. Second, although the results have generalizability 
across geographic regions and across many surgeons, they cannot be generalized to other 
models of GDIs. Third, since patients undergoing combined GDI implantation with 
concomitant other ocular surgery, this large group of patients cannot be generalized to. And 
lastly, the results cannot be generalized to patients who have not had prior eye surgery in low 
risk groups. The GDI arm of the ongoing Primary TVT study will provide more information 
as to the complications in this population.
In summary, when the eye surgeon needs to decide which glaucoma implant an individual 
patient should receive, it is important to consider the success and failure rates, the final IOP 
and number of medications needed, and the risk of complications of various devices. The 
ABC Study has demonstrated comparable success rates between the Ahmed Glaucoma 
Valve FP7 and Baerveldt Glaucoma Implant BG 101-350 implants with different reasons for 
failures in the two groups at five years.10 The Ahmed Glaucoma Valve FP7 tended to fail 
due to inadequate control of IOP resulting in reoperation whereas the Baerveldt Glaucoma 
Implant BG 101-350 tended to fail due to safety endpoints such as hypotony, need for 
explantation of the device, and loss of light perception vision.10 While the Baerveldt 
Glaucoma Implant BG 101-350 provided an additional 2 mmHg of IOP lowering compared 
to the Ahmed Glaucoma Valve FP7,10 the current study demonstrates an increased risk of 
serious complications needing operative correction or resulting in loss of some visual acuity 
associated with the Baerveldt Glaucoma Implant BG 101-350. All of these factors should be 
considered when choosing between these two commonly used aqueous shunts.
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Figure 1. 
Cumulative probability of experiencing a serious complication within five years of surgery 
in the Ahmed Baerveldt Comparison Study.
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Figure 2. 
Cumulative probability of requiring an operation for complications within five years of 
surgery in the Ahmed Baerveldt Comparison Study.
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Figure 3. 
Cumulative probability of phakic subjects requiring cataract extraction within five years of 
surgery in the Ahmed Baerveldt Comparison Study.
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Table 1
Postoperative Interventions after 12 months in the Ahmed Baerveldt Comparison Study
Intervention Ahmed (n = 143) Baerveldt (n = 133)
Anterior chamber reformation 0 1 (1%)
Intravitreal Injection 0 2 (2%)
Needling at slit lamp 1 (1%) 0
Macular laser for CME 1 (1) 0
Laser Trabeculoplasty 0 1 (1%)
Corneal Scraping for Band Keratopathy 0 1 (1%)
Total Number of Patients with Interventions 2 (1.4%) 5 (3.8%)
P = 0.21, Fisher Exact Test
CME – Cystoid Macular Edema
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Table 3
Serious Complications Associated with Reoperation and/or Vision Loss in the Ahmed Baerveldt Comparison 
Study
Ahmed Group (n = 143) Baerveldt Group (n = 133)
Reoperation for complications 16 (14.3%) 24 (19.5%)
Vision loss of ≥ 2 Snellen lines
 Persistent corneal edema 1 1
 Persistent corneal edema + hypotony maculopathy 0 1
 Persistent corneal edema + tube-corneal touch 0 2
 Cystoid macular edema 0 1
Total number of subjects with serious complications† 17 (15.9%) 29 (24.7%)
Data censored after a reoperation for glaucoma.
†
P = 0.034 for the difference in 5-year cumulative serious complication rates between treatment groups from Kaplan-Meier analysis (log rank test 
adjusted for stratum).
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Table 4
Reoperations for Complications in the Ahmed Baerveldt Comparison Study
Ahmed Group (n = 143) Baerveldt Group (n = 133)
Corneal transplant procedure* 3 4
Pars plana vitrectomy 1 3
Surgery for tube occlusion 1 7
YAG laser to clear vitreous from tube 1 1
Surgical iridectomy 1 0
Tube tied off to repair hypotony 1 1
Repair of wound leak 1 1
Tube repositioning/extension 3 1
Revision for tube erosion 2 3
Drainage of suprachoroidal hemorrhage 0 1
Implant explantation 3 3
Total number of patients (cumulative percentage) with reoperations for 
complications†
16 (14.3%) 24 (19.5%)
Data censored after a reoperation for glaucoma.
*
Includes penetrating keratoplasty and Descemet’s stripping automated endothelial keratoplasty.
†One subject in each group had a penetrating keratoplasty and pars plana vitrectomy performed at the same surgery, explaining why there are more 
complications listed for each group than subjects with complications.
P = 0.109 for the difference in 5-year cumulative reoperations for complication rates between treatment groups from Kaplan-Meier analysis (log 
rank test adjusted for stratum).
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